Exploring a Potential Blood Test to Diagnose Major Depressive Disorder (Bio-TestMDD)

This study has been completed.
Sponsor:
Collaborators:
Precision Human Biolaboratories
Cambridge Health Alliance
University of Connecticut
Vanderbilt University
Psychiatric Medicine Associates, L.L.C.
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00705185
First received: June 23, 2008
Last updated: June 7, 2010
Last verified: June 2010
  Purpose

The purpose of this study is to develop a blood test for major depression and measure the effects of ziprasidone monotherapy on these markers.

Specific Aim: Using a multiplex biomarker assay we will measure levels of 16 biomarkers in patients with MDD enrolled in this ancillary study (adjunct to study NCT00555997) and compare these results to those of healthy controls" (defined as research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)) from an existing dataset at PHB.


Condition
Major Depressive Disorder

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Exploring Potential Serum/Plasma-Based Biomarkers as a Test for Major Depressive Disorder Diagnostics ("Bio-Test MDD")

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • 16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls [ Time Frame: Screen visit ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

serum, plasma


Estimated Enrollment: 120
Study Start Date: April 2008
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
2
Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)

Detailed Description:

This proposed study will be an ancillary study to clinical trial NCT00555997 (www.clinicaltrials.gov) entitled: "A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder" (MDD)." Precision Human Biolaboratory ("PHB") is attempting to develop a proprietary blood test intended to potentially serve as a biological marker ("bio-marker") for MDD. Specifically, PHB's research team will employ a unique approach towards developing a diagnostic test for MDD: measures from multiple blood-based biological markers will be obtained from patients with MDD and then analyzed with the use of several interrelated algorithms in order to derive a single biological measure ("bio-marker") with a high predictive value for MDD. PHBs' test panel of blood-based biological markers will consist of a number of cytokines, stress related hormones, and binding proteins that have each been linked to MDD. This innovative test panel is expected to provide general practice physicians with a tool to more accurately identify and classify patients with MDD which, in turn, could potentially , allow for the more effective monitoring of pharmacotherapy (antidepressant drug therapy). Thus, the development of a highly reliable biomarker for MDD could improve the standard of care for depression.

For this ancillary study, 120 antidepressant-free outpatients with MDD who have been deemed eligible to participate in trial NCT00555997 will be recruited from participating centers. Participating subjects will undergo a blood draw during the baseline visit for NCT00555997. Values obtained will be compared with those of "healthy controls" (defined as research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)) from an existing dataset at PHB.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults with Major Depressive Disorder (DSM-IV)

Criteria

Inclusion Criteria:

Age 18-65.

  • Written informed consent.
  • MDD, current according to the fourth version of the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) as diagnosed by the Mini International Neuropsychiatric Interview (MINI; Sheehan et al, 1998).
  • Quick Inventory of Depressive Symptomatology - Self-Rated (QIDS-SR- Trivedi et al, 2004) score of at least 10 at both screen and baseline visits.

Exclusion Criteria:

  • Pregnant women.
  • Women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or a partner with vasectomy).
  • Treatment with antidepressants for 2 weeks prior to the screen visit. If interested in discontinuing their current medication, potential participants must discuss this possibility with the prescribing physician. Study doctors will not implement any form of treatment washout.
  • Patients who no longer meet DSM-IV criteria for MDD during the baseline visit, or patients who demonstrate a 25% or greater reduction in QIDS-SR scores, screening to baseline.
  • Serious suicide or homicide risk, as assessed by the evaluating clinician or a score of 4 on the third item of the HAM-D.
  • Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease.
  • Patients who meet criteria for alcohol or substance dependence, active within the last month.
  • Any bipolar disorder (current or past).
  • Any psychotic disorder (current or past).
  • Psychotic features in the current episode or a history of psychotic features.
  • History of a seizure disorder.
  • Clinical or laboratory evidence of untreated hypothyroidism.
  • Patients requiring excluded medications (see table 1 for details).
  • Prior course of ziprasidone, or intolerance to ziprasidone at any dose.
  • Any investigational psychotropic drug within the last 3 months.
  • Patients with significant cardiac conduction problems on screening electrocardiogram such as atrial fibrillation, atrial flutter, atrio-ventricular block, prolonged or abnormal QTc interval (i.e. QTc>450msec), or prolonged QRS interval.
  • Patients who have suffered a myocardial infarction within the past 12 months, with uncompensated heart failure, or a history of QTc prolongation.
  • Patients with abnormal serum potassium or magnesium levels upon screening.
  • Patients currently taking other drugs that prolong the QTc including dofetilide, sotalol, quinidine, class Ia antiarrhythmics, class III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron methylate, probucol or tacrolimus.
  • Patients who have failed to experience significant clinical improvement following 3 or more antidepressant trials of adequate duration (at least 6 weeks) and dose (minimal effective doses defined as: fluoxetine, paroxetine, citalopram 20mg; sertraline, fluvoxamine 50mg, escitalopram 10mg, paroxetine CR 25mg, venlafaxine 75mg, duloxetine 60mg, bupropion 150mg, 15mg of mirtazapine, trazodone or nefazodone 300mg).
  • The presence of Addison's or Cushing's disease.
  • The presence of rheumatoid arthritis, or systemic lupus erythematosus.
  • The regular use of non-steroidal anti-inflammatory medications or oral steroids.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00705185

Locations
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
United States, Illinois
Psychiatric Medicine Associates, L.L.C.
Chicago, Illinois, United States, 60025
United States, Massachusetts
Massachusetts General Hosptial
Boston, Massachusetts, United States, 02114
Cambridge Health Alliance
Cambridge, Massachusetts, United States, 02139
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Massachusetts General Hospital
Precision Human Biolaboratories
Cambridge Health Alliance
University of Connecticut
Vanderbilt University
Psychiatric Medicine Associates, L.L.C.
Investigators
Principal Investigator: George I Papakostas, M.D. Massachusetts General Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: George I. Papakostas, M.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00705185     History of Changes
Other Study ID Numbers: 2007-P-002525
Study First Received: June 23, 2008
Last Updated: June 7, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Major Depressive Disorder
Blood Test

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms

ClinicalTrials.gov processed this record on April 17, 2014